Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 55.56 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $187.546 thousand which beat the analyst consensus estimate of $2.000 thousand by 9.28K percent.